References
- Boman G. Melanin affinity of a new antituberculous drug, rifampicin, investigated by whole body autoradiography. Acta Ophthalmologica 1973; 51: 367–370
- Daly J. W., Jerina D. M., Witkop B. Arene oxides and the NIH shift: the metabolism, toxicity and carcinogenicity of aromatic compounds. Experimentia 1972; 28: 1129–1149
- Darda V. A., Forster H. J., Stahle H. Metabolischer Abbau von Clonidin. Arzneimittel-Forschung 1978; 28: 255–259
- Doxey J. C., Roach A. G., Smith C. F. C. Studies on RX781094: a selective, potent and specific antagonist of α2-adrenoceptors. British Journal of Pharmacology 1983; 78: 489–505
- Gadie B., Lane A. C., McCarthy P. S., Tulloch I. F., Walter D. S. 2-Alkyl analogues of idazoxan (RX781094) with enhanced antagonist potency and selectivity at central α2-adrenoceptors in the rat. British Journal of Pharmacology 1984; 83: 707–712
- Kato R. Sex-related differences in drug metabolism. Drug Metabolism Review, F. J. DiCarlo. Marcel Dekker Inc. 1974; 1–32
- Larsson B., Tjalve H. Studies on the mechanism of drug-binding to melanin. Biochemical Pharmacology 1979; 28: 1181–1187
- Levvy G. A. The preparation and properties of β-glucuronidase. 4. Inhibition by sugar acids and their lactones. Biochemical Journal 1952; 52: 464–472
- Muir N. C., Lloyd-Jones J. G., Nichols J. D., Clifford J. M. The pharmacokinetics after intravenous and oral administration in man of the α2-adrenoreceptor antagonist idazoxan (RX781094). European Journal of Clinical Pharmacology 1986; 29: 743–745
- Poynter D., Martin L. E., Harrison C., Cook J. Affinity of Labetalol for occular melanin. British Journal of Clinical Pharmacology 1976; 3(Suppl. 3)711–721
- Walter D. S., Flockhart I. R., Haynes M. J., Howlett D. R., Lane A. C., Burton R., Johnson J., Dettmar P. W. Effects of idazoxan on catecholamine systems in rat brain. Biochemical Pharmacology 1984; 33(16)2553–2557